Sonoma Biotherapeutics on Monday hosted a ribbon cutting ceremony at its new research and development center and office space on Seattle’s waterfront.
The biotech company, which has a second location in South San Francisco, has taken over three of four floors in a building formerly occupied by the tech company F5, spanning a total of 83,000 square feet.
Sonoma launched in 2019 and is focused on treating autoimmune and inflammatory diseases in which a person’s immune system over-responds and attacks the wrong cells. It’s pursuing treatments that use what are known as regulatory T (Treg) cells to protect the cells under attack.